Research summaries for everyoneNot medical advice
Semax research reference vial, Elevated Pharma

Research reference · Cognition & Sleep

Semax

Semax is a synthetic heptapeptide derived from ACTH(4-10). It is registered as a medicine in Russia and studied mainly in stroke and nervous-system models.

Published by Elevated Pharma ·

Cognition & SleepPreclinical and analytical literature

Identity

What is Semax?

A synthetic heptapeptide, Met-Glu-His-Phe-Pro-Gly-Pro.

Research context

What has Semax been studied for?

Animal studies cover stroke, spinal cord injury and Alzheimer’s models; Russian clinical studies examine stroke recovery but are mostly not placebo-controlled.

Evidence boundary

What does the research not show?

The cited research does not establish an FDA-approved use or a human safety conclusion.

U.S. status · November 7, 2026

Is Semax FDA-approved?

FDA removed it from its Category 2 compounding list in April 2026, and FDA’s compounding advisory committee recommended it for the 503A bulks list on July 24, 2026 (recommended). On October 28, 2026, HHS issued an interim policy saying it will not take enforcement action against licensed pharmacies and physicians that compound it under listed conditions, such as FDA-registered sourcing, a certificate of analysis and safety reporting. It is not FDA-approved, and the policy does not cover research-use-only material.

Research updates

What’s new

Dated developments for Semax, newest first. See all research updates.

  1. HHS interim compounding policy

    HHS published an enforcement-discretion policy covering BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500 for licensed pharmacies and physicians. Comments close November 13, 2026.

    Read the source
  2. FDA advisory committee votes

    FDA’s Pharmacy Compounding Advisory Committee voted on seven peptides over July 23–24, recommending six and declining emideltide (DSIP).

    Read the source

Key studies

The main Semax research

Selected from PubMed: human trials first, then reviews, then foundational laboratory work. Each finding applies to the material and setting studied.

Search all 210 PubMed records for Semax · Counts and selections checked November 7, 2026.

Reference identifiers

Semax identity data

Database identity describes the reference substance, not any specific material or lot.

Primary name
Semax
Also indexed as
Met-Glu-His-Phe-Pro-Gly-Pro
Sequence
Met-Glu-His-Phe-Pro-Gly-Pro
Molecular formula
C37H51N9O10S
Molecular mass
813.9 g/mol
PubChem CID
9811102

Official & primary sources

Regulatory and database records

Citation does not imply an Elevated Pharma partnership or endorsement.